Lycera is a technology company.
Lycera has raised $36.0M across 1 funding round.
Key people at Lycera.
Lycera has raised $36.0M in total across 1 funding round.
Lycera has raised $36.0M in total across 1 funding round.
Lycera's investors include ARCH Venture Partners, Canaan Partners.
Lycera is a biopharmaceutical company headquartered in Ann Arbor, Michigan, focused on developing small-molecule therapies to treat cancer and autoimmune diseases by modulating the immune response through immune metabolism, cell signaling, and immune cell differentiation.[1][2] It advances a proprietary portfolio of small molecules, either suppressing or activating immune responses, with programs targeting conditions like inflammatory bowel disease (e.g., lead candidate LYC-30937, planned for clinical testing in 2015), ulcerative colitis, arthritis, and broader autoimmune disorders; the company has collaborated with Merck and maintains a drug pipeline including Phase 2 assets like parimifasor (discontinued for ulcerative colitis) and preclinical/pending candidates targeting F1F0-ATPase, RORγt, and ATPase modulators.[1][4] Lycera serves patients with unmet needs in oncology and immunology, solving challenges in immune dysregulation via novel immunomodulators, with early revenue around $6.9 million and about 30 employees as of available records.[1]
Lycera emerged as a biotech innovator in Ann Arbor, leveraging world-class expertise in complementary research areas to build its immune-focused pipeline, though specific founding year and founders are not detailed in available sources.[1] Key early milestones include establishing collaborations with Merck for autoimmune therapies and advancing wholly owned programs, such as LYC-30937 for inflammatory bowel disease, set for clinical entry in early 2015; the leadership team brings deep drug discovery, development, commercialization experience, and ties to global thought leaders.[1] Investors like InterWest Partners provided backing, fueling growth amid a tech stack including Automattic, PHP, Google, and Cloudflare tools.[1] The company gained traction through its pipeline, with clinical trials starting as early as 2016 (e.g., December 5 and 1) and a 2018 program launch, positioning it within Michigan's life sciences ecosystem like the Michigan Life Sciences & Innovation Center.[2][4]
Lycera rides the wave of precision immunology, capitalizing on advances in small-molecule immunomodulation amid rising demand for targeted therapies in autoimmune diseases and oncology, where immune checkpoint and metabolic modulators address limitations of biologics like high costs and delivery challenges.[1][2][3] Timing aligns with post-2010s biotech booms in oral small molecules for immunology (e.g., JAK inhibitors' success), amplified by collaborations like Merck's, which de-risk development and tap big pharma resources.[1] Market forces favoring Lycera include aging populations driving autoimmune/cancer prevalence, regulatory pushes for oral alternatives, and Michigan's life sciences hubs fostering innovation; it influences the ecosystem by pioneering RORγt and ATPase targets, contributing to pipeline diversity and secondary market liquidity via platforms like Forge Global.[2][4][5]
Lycera's path forward hinges on resurrecting or partnering dormant pipeline assets like parimifasor (post-Phase 2 discontinuation) and pending RORγt programs, potentially via new trials or acquisitions in a consolidating biotech sector hungry for immune modulators.[4][5] Trends like AI-driven drug design, combination immunotherapies, and oral drug dominance will shape its trajectory, especially if it leverages its Ann Arbor base for talent and funding amid secondary market interest.[1][5] Influence may evolve through buyouts by majors like Merck successors or IPOs if milestones hit, amplifying its role in underserved immunology niches—echoing its core mission to transform immune disease treatment from the ground up.[1]
Key people at Lycera.
Lycera has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series A in May 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2009 | $36.0M Series A | ARCH Venture Partners, Canaan Partners |
